List of Excipients in Branded Drug POSACONAZOLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ENDO USA Inc	POSACONAZOLE	posaconazole	0254-2045	CELLULOSE, MICROCRYSTALLINE
ENDO USA Inc	POSACONAZOLE	posaconazole	0254-2045	CROSCARMELLOSE SODIUM
ENDO USA Inc	POSACONAZOLE	posaconazole	0254-2045	FERRIC OXIDE YELLOW
ENDO USA Inc	POSACONAZOLE	posaconazole	0254-2045	HYDROXYPROPYL CELLULOSE
ENDO USA Inc	POSACONAZOLE	posaconazole	0254-2045	HYPROMELLOSE ACETATE SUCCINATE 06081224

Generic Drugs Containing POSACONAZOLE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	posaconazole	0054-0449	CITRIC ACID MONOHYDRATE
Hikma Pharmaceuticals USA Inc	posaconazole	0054-0449	DIMETHICONE
Hikma Pharmaceuticals USA Inc	posaconazole	0054-0449	GLYCERIN
Hikma Pharmaceuticals USA Inc	posaconazole	0054-0449	HYDROXYETHYL CELLULOSE
Hikma Pharmaceuticals USA Inc	posaconazole	0054-0449	POLYOXYL 35 CASTOR OIL

What are the Most Frequently-Used Excipients in POSACONAZOLE?

# Of NDCs	Excipient
7	BETADEX SULFOBUTYL ETHER SODIUM
23	CELLULOSE, MICROCRYSTALLINE
1	CITRIC ACID MONOHYDRATE
25	CROSCARMELLOSE SODIUM
1	DIMETHICONE

Posaconazole Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Posaconazole is a formulation-driven antifungal with commercial opportunity concentrated in bioavailability, dosage-form substitution, pediatric administration, renal safety, and therapeutic-drug-monitoring support. The drug has low aqueous solubility and absorption that varies materially by formulation, food intake, gastrointestinal conditions, and administration method. The strongest product strategy is therefore not a simple active-ingredient generic. It is a differentiated oral or parenteral system that improves exposure consistency, administration flexibility, or patient acceptability.

What formulation problem must excipients solve for posaconazole?

Posaconazole is a triazole antifungal with poor aqueous solubility. Its absorption is highly dependent on the formulation and, for the oral suspension, food intake. The commercial formulation objective is to maintain adequate dissolved drug in the gastrointestinal tract long enough to achieve therapeutic exposure.

The principal formulation constraints are:

Constraint	Commercial consequence
Low aqueous solubility	Requires wetting, dispersion, amorphous-solid, lipid, or cyclodextrin strategies
Food-dependent absorption of suspension	Creates exposure variability and administration restrictions
Variable absorption in mucositis, diarrhea, or gastrointestinal graft-versus-host disease	Favors delayed-release tablets, alternative oral systems, or intravenous therapy
Need for therapeutic drug monitoring	Creates opportunities for adherence, sampling, and dose-adjustment services
Intravenous formulation dependence on SBECD	Limits use in severe renal impairment and creates formulation-substitution opportunities
Pediatric and dysphagia requirements	Supports oral multiparticulates, granules, suspensions, and sprinkle formulations
Strong systemic antifungal potency	Makes dose uniformity and low-dose content uniformity critical

The excipient strategy must preserve posaconazole in a physically stable, readily dissolving state. It must also avoid excessive food dependence, minimize precipitation after gastric dilution, and support a commercially acceptable shelf life.

What excipients are used in Noxafil posaconazole formulations?

Merck’s Noxafil product line uses different excipient systems for the oral suspension, delayed-release tablets, and injection. The formulations are not interchangeable on a milligram-for-milligram basis because they produce different pharmacokinetic profiles.

Noxafil oral suspension

The 40 mg/mL oral suspension uses a structured aqueous dispersion system. The FDA label identifies excipients including polysorbate 80, simethicone, sodium benzoate, sodium citrate dihydrate, citric acid monohydrate, glycerin, xanthan gum, titanium dioxide, and flavoring components.[1]

The functional roles are broadly as follows:

Excipient class	Likely formulation role
Polysorbate 80	Wetting and dispersion of hydrophobic posaconazole
Xanthan gum	Suspension viscosity and particle settling control
Glycerin	Humectancy, viscosity, and mouthfeel
Sodium citrate and citric acid	pH adjustment and buffering
Sodium benzoate	Preservative function
Simethicone	Foam-control function
Titanium dioxide and flavor	Appearance and palatability

The commercial weakness of the suspension is its dependence on food, particularly a high-fat meal or nutritional supplement. The label warns that exposure is lower when the suspension is administered without food or with a low-fat meal.[1] This creates a formulation opportunity for a generic or lifecycle product with less food dependence.

Noxafil delayed-release tablets

The delayed-release tablet uses a solid oral excipient platform rather than an aqueous suspension. The label identifies excipients including hypromellose acetate succinate, microcrystalline cellulose, croscarmellose sodium, povidone, colloidal silicon dioxide, and magnesium stearate, together with conventional coating materials.[1]

The critical excipient is hypromellose acetate succinate, a pH-dependent polymer commonly used in enteric or delayed-release systems. It helps protect the dosage form in the stomach and promotes release in the higher-pH environment of the small intestine.

The tablet provides more consistent exposure than the suspension in many clinical settings and is less dependent on a high-fat meal. It is the principal commercial benchmark for an improved oral posaconazole product.

Noxafil injection

The intravenous formulation contains sulfobutyl ether beta-cyclodextrin sodium, commonly called SBECD, as the major solubilizing excipient. It also contains edetate disodium and pH-adjusting agents.[1]

SBECD forms inclusion complexes with hydrophobic drug molecules and increases apparent aqueous solubility. The approach enables an intravenous posaconazole solution but introduces a renal-exposure issue because SBECD is primarily eliminated through the kidneys. The prescribing information restricts use of the injection in patients with estimated glomerular filtration rates below 50 mL/min because of the risk of accumulation of the excipient.[1]

This limitation creates a direct development opportunity for a parenteral formulation based on a lower-burden solubilizer, a lower-excipient-dose system, or a different concentration and infusion architecture.

How do posaconazole formulations compare commercially?

Product characteristic	Oral suspension	Delayed-release tablet	Intravenous injection
Main excipient strategy	Surfactant and polymeric suspension	Enteric or delayed-release solid dosage form	Cyclodextrin solubilization
Strength	40 mg/mL	100 mg per tablet	18 mg/mL
Food dependence	Material	Lower than suspension	None
Administration flexibility	Requires shaking and calibrated dosing	Limited by swallowing ability	Requires infusion access
Main patient limitation	Variable absorption and food requirement	Tablet swallowing and gastrointestinal release	Renal limitations related to SBECD
Generic complexity	Medium	High	High
Differentiation opportunity	High	Moderate to high	High

The delayed-release tablet has the strongest overall commercial position for routine adult prophylaxis and treatment. The suspension remains relevant for patients unable to swallow tablets, but its food-related pharmacokinetic limitations reduce its attractiveness. The injection is clinically important when oral administration is not feasible, yet its excipient profile and renal restrictions create a narrower market.

What excipient strategies offer the strongest commercial opportunity?

Amorphous solid dispersions

An amorphous solid dispersion can improve dissolution by maintaining posaconazole in a high-energy, noncrystalline state. Suitable polymer families may include hypromellose acetate succinate, hypromellose, polyvinylpyrrolidone, copovidone, and related precipitation-inhibiting polymers.

The development challenge is physical stability. Posaconazole can recrystallize during storage or after exposure to gastrointestinal fluid. A successful product would require evidence of:

• Stable amorphous content through shelf life
• Rapid dissolution across physiologic pH conditions
• Controlled precipitation after intestinal dilution
• Consistent exposure under fed and fasted conditions
• Acceptable tablet size and manufacturability

A solid-dispersion product could compete with the delayed-release tablet if it reduces food dependence without relying on the same release mechanism.

Lipid-based formulations

Self-emulsifying drug-delivery systems and other lipid-based formulations can improve solubilization in the gastrointestinal tract. Candidate excipients include medium-chain triglycerides, mono- and diglycerides, polysorbates, polyoxyl surfactants, and hydrophilic cosolvents.

The commercial value would be highest in a compact softgel, capsule, or sachet that:

• Reduces dependence on high-fat meals
• Is easier to administer than the suspension
• Avoids the size of a large delayed-release tablet
• Supports use in patients with impaired swallowing

The main risks are capsule compatibility, oxidative stability, gastrointestinal tolerability, dose loading, and precipitation after dilution in gastrointestinal fluid.

Nanocrystal and nanosuspension systems

Nanocrystals increase surface area and can improve dissolution without requiring a large quantity of surfactant or polymer. The approach may support an oral suspension with lower food dependence or a concentrated liquid product.

The critical development controls are particle-size distribution, redispersibility, crystal-form stability, and resistance to agglomeration. A nanosuspension must also demonstrate that the improved dissolution produces clinically meaningful exposure rather than only faster in vitro release.

Multiparticulate and pediatric systems

Pediatric patients, patients with dysphagia, and patients receiving enteral nutrition are underserved by tablet-centered products. Multiparticulate granules or coated pellets could be administered in soft food or through selected feeding tubes.

A viable product would need:

• Low-dose flexibility
• Minimal taste and odor
• No clinically meaningful interaction with soft foods
• Low sedimentation or agglomeration
• Tube compatibility
• Uniform dose recovery from the container
• Stable performance after reconstitution or sprinkling

Taste masking is a major issue. Polymer coatings, lipid barriers, ion-exchange approaches, and flavor systems may improve acceptability, but the coating must not delay drug release excessively or create dose loss in the mouth or feeding tube.

Alternative injectable solubilizers

The parenteral market offers a technically demanding but potentially valuable opportunity. Replacing or reducing SBECD could improve use in renal impairment. Options include:

• Alternative cyclodextrin derivatives
• Mixed-solubilizer systems
• Lipid emulsions
• Nanoparticle dispersions
• Colloidal or micellar systems
• Lower-dose concentrated formulations

Any replacement must address hemolysis, infusion-site tolerability, particulate control, compatibility with infusion materials, extractables and leachables, and terminal sterilization or aseptic processing.

What formulation patents protect posaconazole products?

Posaconazole intellectual property has historically covered the active compound, antifungal uses, solid forms, formulations, and manufacturing processes. Commercial freedom-to-operate analysis must separate four categories:

Patent category	Relevance to posaconazole competition
Compound patents	Historically controlled the active ingredient and earliest entry
Formulation patents	Can protect delayed release, dispersions, suspensions, injection systems, or excipient combinations
Method-of-use patents	May cover prophylaxis, treatment, dosing, or patient subgroups
Manufacturing patents	Can create process barriers even after compound protection expires

The practical risk is usually higher for delayed-release tablets and complex injections than for a simple oral suspension. A formulation patent may not need to claim posaconazole broadly. It can claim a narrow combination of particle size, polymer ratio, release profile, dissolution condition, or excipient concentration.

Patent claims that deserve particular scrutiny include:

• Posaconazole combined with hypromellose acetate succinate or another enteric polymer
• Amorphous posaconazole compositions
• Defined dissolution profiles
• Specific particle-size distributions
• SBECD-containing injectable solutions
• Stable aqueous suspensions with surfactant and viscosity-control systems
• Manufacturing processes that control polymorphism or crystallinity
• Dosage regimens for prophylaxis in immunocompromised patients

A generic developer should analyze product-by-process exposure, not only composition claims. An apparently different excipient system may still infringe a process or performance claim if the finished product meets the claimed structural parameters.

What is the Orange Book and FDA regulatory status of posaconazole?

Noxafil is FDA-approved in multiple dosage forms, including oral suspension, delayed-release tablets, and injection. The approved uses include prophylaxis of invasive Aspergillus and Candida infections in patients at high risk because of severe immunocompromise.[1]

The FDA Orange Book is the controlling source for currently listed patents and exclusivity associated with approved Noxafil products.[2] The listing analysis must be performed separately by dosage form and strength because a patent listed against the delayed-release tablet does not automatically block an oral suspension or injection ANDA.

Relevant regulatory pathways include:

Product strategy	Likely FDA pathway
Same oral suspension, strength, route, and labeling	ANDA
Same delayed-release tablet	ANDA with bioequivalence and product-specific requirements
New pediatric granules or sprinkle product	505(b)(2) or NDA, depending on differences
New injectable solubilizer	505(b)(2) or NDA
New dosage regimen or patient population	505(b)(2) or supplemental NDA
Novel delivery technology	505(b)(2), NDA, or potentially a drug-device combination pathway

For an ANDA, the central legal issue is whether listed patents require Paragraph IV certification. A Paragraph IV applicant may challenge listed patents by asserting noninfringement, invalidity, or unenforceability. The commercial timing then depends on patent litigation, the statutory 30-month stay, first-applicant exclusivity where applicable, and any settlement agreement.[3]

When does posaconazole lose exclusivity and face generic entry?

Posaconazole has already moved beyond the period in which compound exclusivity alone determines market access. Current competition depends on dosage form, listed patents, regulatory exclusivity, settlement terms, and the complexity of demonstrating bioequivalence.

The principal entry scenarios are:

Oral suspension entry

This is the most technically accessible generic opportunity. A competitor can target the established surfactant-polymer suspension platform, but it must demonstrate dose uniformity, redispersibility, preservative performance, microbiological quality, and bioequivalence.

Commercial pricing pressure is likely to be substantial because the product has limited formulation complexity relative to the tablet and injection.

Delayed-release tablet entry

This is a more valuable target because the tablet has stronger clinical positioning and higher switching potential. The main barriers are:

• Delayed-release performance
• Food-effect comparison
• Dissolution across multiple pH stages
• Physical form and crystallinity
• Product-specific FDA requirements
• Listed formulation patents
• Manufacturing scale-up

A successful tablet generic could take share from both the branded tablet and the suspension, particularly in institutional antifungal prophylaxis.

Injection entry

The injection is the most difficult target because of sterile manufacturing, cyclodextrin control, infusion compatibility, and renal-use restrictions. A conventional SBECD-based generic may be feasible, but a differentiated renal-safer product would likely require a more extensive regulatory package.

Which companies are challenging posaconazole, and what is the competitive landscape?

Competition is likely to come from three groups:

1. Generic manufacturers pursuing ANDAs for the oral suspension or delayed-release tablet.
2. Specialty pharmaceutical companies developing improved oral delivery systems.
3. Hospital-focused manufacturers targeting sterile injectable supply and shortage resilience.

The strongest competitive advantages will not necessarily come from the lowest active-ingredient cost. They will come from:

• Reliable supply of complex excipients
• Demonstrated bioequivalence under fed and fasted conditions
• Smaller tablet or flexible liquid dosing
• Better pediatric acceptability
• Reduced food dependence
• Stable sterile manufacturing
• Institutional contracting and antifungal stewardship support

Posaconazole also competes clinically with voriconazole, isavuconazole, and other mold-active antifungals. That competition limits the pricing headroom for a reformulation. A new posaconazole product must show a practical advantage in administration, exposure consistency, safety, or total treatment cost.

What licensing and partnership opportunities exist?

Licensing opportunities are most attractive in four areas:

Excipient and formulation technology

A formulation company with a validated amorphous dispersion, nanocrystal, or lipid platform could license the technology to a generic or specialty pharmaceutical partner. The value is higher if the platform has human pharmacokinetic data with reduced food effect.

Pediatric and enteral administration

A sprinkle, granule, or tube-compatible product could support licensing to a hospital pharmaceutical company. Pediatric exclusivity and orphan or pediatric development incentives may improve the commercial case, depending on the indication and development plan.

Injectable reformulation

A renal-safer injectable product could command a premium if it shows clinically meaningful use in patients for whom the current SBECD formulation is unsuitable. The development cost and sterile manufacturing requirements make a partnership more likely than a small standalone launch.

Therapeutic-drug-monitoring services

Posaconazole exposure is commonly monitored in high-risk patients. A commercial package combining formulation, adherence support, pharmacokinetic testing, and dose-management tools could differentiate an otherwise interchangeable product. This would be a service-led strategy rather than an excipient-only strategy.

How strong is the posaconazole patent estate?

The estate is strongest where formulation complexity creates measurable product differences. Delayed-release tablets and injections have more defensible technical features than a conventional suspension.

Patent strength depends on:

• Claim breadth
• Expiration dates
• Continuation and divisional filings
• Written-description support
• Enablement of the claimed excipient range
• Availability of noninfringing alternatives
• Whether the patent claims the product, process, or performance
• Orange Book listing status
• Litigation and settlement history

A narrow claim to a specific polymer ratio or dissolution profile may be commercially important even if competitors can design around it. Conversely, a broad formulation claim may face validity risk if prior art discloses the same solubilizer, polymer, or dosage-form concept.

What generic launch risks exist for posaconazole?

The principal risks are:

Risk	Impact
Failure to match exposure under fed and fasted conditions	ANDA approval delay or clinical substitution concerns
Food-effect differences	Loss of therapeutic reliability
Crystallization during storage	Dissolution failure and batch rejection
Suspension sedimentation	Dose nonuniformity
Poor palatability	Pediatric and adherence failure
SBECD-related renal limitations	Narrow injectable market
Patent litigation	Delayed launch and legal expense
Institutional contracting pressure	Rapid price erosion
Competing mold-active antifungals	Limited premium pricing
Manufacturing variability	Supply interruptions and regulatory scrutiny

The highest-value launch model is a product that combines generic economics with a clinically recognizable formulation advantage. A direct tablet copy may win through price, while a differentiated liquid, pediatric, or renal-use product can support a higher margin.

What is the revenue exposure and commercial outlook?

Posaconazole revenue is exposed to generic substitution, hospital purchasing pressure, and therapeutic competition. Revenue erosion will vary by dosage form:

• Oral suspension revenue is most vulnerable to low-cost generic entry.
• Delayed-release tablet revenue is more defensible because of administration convenience and exposure consistency.
• Injection revenue is protected by sterile manufacturing complexity but constrained by the SBECD renal limitation.
• Differentiated pediatric, enteral, and renal-use products could create new revenue rather than merely defend existing sales.

The most attractive investment thesis is a formulation or delivery platform that addresses a documented clinical weakness: food dependence, gastrointestinal absorption variability, inability to swallow tablets, or renal restrictions on intravenous treatment.

Key Takeaways

• Posaconazole is a formulation-sensitive drug whose commercial value depends heavily on excipient selection.
• The oral suspension uses surfactant, viscosity, buffering, preservative, and flavor systems but has important food-related absorption limitations.
• The delayed-release tablet is commercially stronger because it improves administration and exposure consistency.
• SBECD enables the injectable formulation but creates a renal-use limitation.
• The best formulation opportunities are amorphous dispersions, lipid systems, nanocrystals, pediatric multiparticulates, and alternative injectable solubilizers.
• Generic entry risk is highest for the oral suspension and commercially most consequential for the delayed-release tablet.
• Orange Book analysis must be performed by dosage form and strength, with separate review of formulation, method-of-use, and manufacturing patents.
• A differentiated posaconazole product needs a measurable benefit in food independence, pediatric administration, renal suitability, or exposure consistency.

FAQs

Can polysorbate 80 be replaced in a posaconazole oral suspension?

Yes. Candidate replacements include poloxamers, other nonionic surfactants, lipid-based solubilizers, and nanocrystal systems. The replacement must preserve dissolution, suspension uniformity, taste, microbial stability, and bioequivalence.

Is a posaconazole delayed-release tablet more difficult to genericize than the oral suspension?

Yes. The tablet requires control of enteric release, dissolution across pH conditions, food-effect performance, physical form, and product-specific FDA requirements. The suspension has greater food dependence but fewer delayed-release manufacturing controls.

Can a posaconazole injection avoid SBECD?

Potentially. Alternative cyclodextrins, lipid systems, micelles, and nanoparticle approaches may reduce or eliminate SBECD, but each requires extensive evaluation of sterility, tolerability, stability, infusion compatibility, and pharmacokinetics.

What is the best posaconazole product for pediatric development?

A taste-masked granule, sprinkle, or tube-compatible multiparticulate product is the strongest candidate. It should permit weight-based dosing and avoid the food restrictions associated with the conventional suspension.

Does a new posaconazole excipient system automatically avoid patent infringement?

No. A new excipient does not eliminate risk from formulation, process, method-of-use, or performance claims. Freedom-to-operate analysis must review the specific product architecture and current Orange Book listings.

References

1. U.S. Food and Drug Administration. (2024). Noxafil (posaconazole) prescribing information. Merck Sharp & Dohme LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs

4. Krishna, G., Moton, A., Ma, L., Medlock, M. M., McLeod, J., & beresford, A. (2009). Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions. Antimicrobial Agents and Chemotherapy, 53(3), 958-966.

5. Krishna, G., Ma, L., Martinho, M., O’Mara, E., & Kantesaria, B. (2009). A new solid oral tablet formulation of posaconazole compared with the oral suspension. Antimicrobial Agents and Chemotherapy, 53(9), 3876-3882.

6. Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y. T., Petrikkos, G., Hardalo, C., Suresh, R., & Herbrecht, R. (2007). Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. New England Journal of Medicine, 356(4), 348-359.

7. U.S. Food and Drug Administration. (2023). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents